FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1899180072> ?p ?o ?g. }

• W1899180072 endingPage "22360" @default.
• W1899180072 startingPage "22348" @default.
• W1899180072 abstract "// Katherine E. Hutchinson 1 , Douglas B. Johnson 2 , Adam S. Johnson 3 , Violeta Sanchez 2 , Maria Kuba 3 , Pengcheng Lu 4 , Xi Chen 4 , Mark C. Kelley 5 , Qingguo Wang 6 , Zhongming Zhao 1, 6 , Mark Kris 7 , Michael F. Berger 8, 9 , Jeffrey A. Sosman 2 , William Pao 2, 10 1 Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA 2 Department of Medicine/Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA 3 Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA 4 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA 5 Department of Surgery, Division of Surgical Oncology and Endocrine Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA 6 Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA 7 Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA 8 Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA 9 Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA 10 Currently an employee of Roche Pharma Research and Early Development, Basel, Switzerland Correspondence to: Katherine E. Hutchinson, e-mail: katie.hutchinson@vanderbilt.edu Keywords: melanoma, ERBB, DUSP4, trametinib, afatinib Received: April 09, 2015      Accepted: June 01, 2015      Published: June 13, 2015 ABSTRACT Melanomas are characterized by activating “driver” mutations in BRAF, NRAS, KIT, GNAQ, and GNA11. Resultant mitogen-activated protein kinase (MAPK) pathway signaling makes some melanomas susceptible to BRAF (BRAF V600 mutations), MEK1/2 (BRAF V600, L597, fusions; NRAS mutations), or other kinase inhibitors (KIT), respectively. Among driver-negative (“pan-negative”) patients, an unexplained heterogeneity of response to MEK1/2 inhibitors has been observed. Analysis of 16 pan-negative melanoma cell lines revealed that 8 (50%; termed Class I) are sensitive to the MEK1/2 inhibitor, trametinib, similar to BRAF V600E melanomas. A second set (termed Class II) display reduced trametinib sensitivity, paradoxical activation of MEK1/2 and basal activation of ERBBs 1, 2, and 3 (4 lines, 25%). In 3 of these lines, PI3K/AKT and MAPK pathway signaling is abrogated using the ERBB inhibitor, afatinib, and proliferation is even further reduced upon the addition of trametinib. A potential mechanism of ERBB activation in Class II melanomas is minimal expression of the ERK1/2 phosphatase, DUSP4, as ectopic restoration of DUSP4 attenuated ERBB signaling through potential modulation of the ERBB ligand, amphiregulin (AREG). Consistent with these data, immunohistochemical analysis of patient melanomas revealed a trend towards lower overall DUSP4 expression in pan-negative versus BRAF- and NRAS-mutant tumors. This study is the first to demonstrate that differential ERBB activity in pan-negative melanoma may modulate sensitivity to clinically-available MEK1/2 inhibitors and provides rationale for the use of ERBB inhibitors, potentially in combination with MEK1/2 inhibitors, in subsets of this disease." @default.
• W1899180072 created "2016-06-24" @default.
• W1899180072 creator A5006317694 @default.
• W1899180072 creator A5006688612 @default.
• W1899180072 creator A5008171524 @default.
• W1899180072 creator A5023047936 @default.
• W1899180072 creator A5025067315 @default.
• W1899180072 creator A5037092952 @default.
• W1899180072 creator A5037252693 @default.
• W1899180072 creator A5039791495 @default.
• W1899180072 creator A5040559366 @default.
• W1899180072 creator A5052925002 @default.
• W1899180072 creator A5062616992 @default.
• W1899180072 creator A5074540558 @default.
• W1899180072 creator A5075566772 @default.
• W1899180072 creator A5088553415 @default.
• W1899180072 date "2015-06-13" @default.
• W1899180072 modified "2023-10-15" @default.
• W1899180072 title "ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma" @default.
• W1899180072 cites W125335819 @default.
• W1899180072 cites W1967953130 @default.
• W1899180072 cites W1982443780 @default.
• W1899180072 cites W1988379285 @default.
• W1899180072 cites W1989121777 @default.
• W1899180072 cites W1989790390 @default.
• W1899180072 cites W1990774346 @default.
• W1899180072 cites W1997232062 @default.
• W1899180072 cites W1998193510 @default.
• W1899180072 cites W2000798782 @default.
• W1899180072 cites W2009642188 @default.
• W1899180072 cites W2032211985 @default.
• W1899180072 cites W2032545841 @default.
• W1899180072 cites W2038264590 @default.
• W1899180072 cites W2038683568 @default.
• W1899180072 cites W2043398720 @default.
• W1899180072 cites W2043696829 @default.
• W1899180072 cites W2049449785 @default.
• W1899180072 cites W2052005627 @default.
• W1899180072 cites W2053129129 @default.
• W1899180072 cites W2053520756 @default.
• W1899180072 cites W2054918837 @default.
• W1899180072 cites W2061695178 @default.
• W1899180072 cites W2063432148 @default.
• W1899180072 cites W2074849291 @default.
• W1899180072 cites W2077517114 @default.
• W1899180072 cites W2078443595 @default.
• W1899180072 cites W2083435672 @default.
• W1899180072 cites W2085573901 @default.
• W1899180072 cites W2095659509 @default.
• W1899180072 cites W2097995306 @default.
• W1899180072 cites W2100614336 @default.
• W1899180072 cites W2100738068 @default.
• W1899180072 cites W2101653483 @default.
• W1899180072 cites W2103557568 @default.
• W1899180072 cites W2106494998 @default.
• W1899180072 cites W2108068107 @default.
• W1899180072 cites W2112463549 @default.
• W1899180072 cites W2118982164 @default.
• W1899180072 cites W2125333956 @default.
• W1899180072 cites W2125883153 @default.
• W1899180072 cites W2128327828 @default.
• W1899180072 cites W2128542677 @default.
• W1899180072 cites W2128899239 @default.
• W1899180072 cites W2132167584 @default.
• W1899180072 cites W2133867160 @default.
• W1899180072 cites W2135751334 @default.
• W1899180072 cites W2136474966 @default.
• W1899180072 cites W2139236349 @default.
• W1899180072 cites W2141393790 @default.
• W1899180072 cites W2144096834 @default.
• W1899180072 cites W2146772089 @default.
• W1899180072 cites W2147474070 @default.
• W1899180072 cites W2156228893 @default.
• W1899180072 cites W2156266404 @default.
• W1899180072 cites W2158416296 @default.
• W1899180072 cites W2160834915 @default.
• W1899180072 cites W2161821474 @default.
• W1899180072 cites W2163188200 @default.
• W1899180072 cites W2167202878 @default.
• W1899180072 cites W2168143310 @default.
• W1899180072 cites W2560367415 @default.
• W1899180072 cites W4237915251 @default.
• W1899180072 doi "https://doi.org/10.18632/oncotarget.4255" @default.
• W1899180072 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4673168" @default.
• W1899180072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26084293" @default.
• W1899180072 hasPublicationYear "2015" @default.
• W1899180072 type Work @default.
• W1899180072 sameAs 1899180072 @default.
• W1899180072 citedByCount "11" @default.
• W1899180072 countsByYear W18991800722017 @default.
• W1899180072 countsByYear W18991800722019 @default.
• W1899180072 countsByYear W18991800722020 @default.
• W1899180072 countsByYear W18991800722022 @default.
• W1899180072 countsByYear W18991800722023 @default.
• W1899180072 crossrefType "journal-article" @default.
• W1899180072 hasAuthorship W1899180072A5006317694 @default.
• W1899180072 hasAuthorship W1899180072A5006688612 @default.
• W1899180072 hasAuthorship W1899180072A5008171524 @default.

• next